Australia, Nov. 13 -- Inventia Pty. Ltd., owns the trademark (2361708) for 'INVENTIA' till June 2, 2033.

Status: registered: Registered/protected

Classes: 5 [Surgical grafts (living tissues); engineered living tissues and 3D cell cultures for medical and surgical use; tissue-regenerative medical preparations; biological tissue cultures for medical purposes; biological preparations use for in cell cultures (medical)], 7 [3D printers; computerised equipment for the generation of 3D shaped parts; machines, namely, 3D bioprinters for the printing of living cells and tissues or printing 3D cell structures; cartridges for containing printing materials for use with 3D printers; cartridges for containing bioprinting materials for use with 3D printers; printing cartridges for containing biomaterials and reagents for use with 3D printers; printing cartridges for containing bio-ink for use with 3D printers; robotic handling apparatus; accessories and spare parts for three dimensional (3D) printers for the production of biological materials, namely print heads for three dimensional (3D) printers; machines, namely, three dimensional (3D) printer for the printing of engineered living tissues; three dimensional (3D) printers; computerised equipment for the generation of 3D shaped parts; parts and fittings therefor; none of the foregoing goods being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases], 9 [Laboratory robots; downloadable software, being software for monitoring and controlling communication between computers and scientific or medical apparatus, software for operating and controlling 3D printers for scientific or medical purposes, downloadable operating software to control laboratory apparatus for fabrication of three dimensional (3D) engineered living tissues, and software for the purpose of the manufacture of medical products by means of a 3D printer; electronic components for use in connection with laboratory robots; laboratory instruments and apparatus, including cell assembly apparatus for laboratory use for fabrication of three dimensional (3D) engineered living tissues; electronic publications; parts and fittings for all of the foregoing, including electronic control panels with digital displays for the control of three dimensional (3D) printers; none of the foregoing goods being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases], 10 [Surgical robotics for soft tissue repair; surgical robotics for delivery of materials to wound or injury sites; none of the foregoing goods containing or comprising imaging apparatus or instruments or being for use with imaging apparatus or instruments; none of the foregoing goods being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases], 35 [Data management; retail and wholesale services for pharmaceutical, medical, scientific, laboratory and 3D printing consumables and supplies; administrative processing of purchase orders; computerised stock ordering and purchasing; computerised data processing; compilation of scientific information; maintenance of registers (for others), including registers relating to device history and maintenance history: none of the foregoing services being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases] and 42 [Scientific and technological services and research and design relating thereto; industrial analysis, industrial research and industrial design services; design and development of computer software; software-as-a-service; provision of online non-downloadable software (application service provider); computer support services (programming and software installation, repair and maintenance services); analysis of statistical data for scientific research; design services, including design of software, design of biological materials, design services relating to printing and product design; research relating to design; laboratory research; biomedical research; cloud computing; advisory services relating to scientific products and scientific research; scientific research into the development of new products; providing technical support services regarding medical and diagnostic laboratory instruments and systems; providing a non-downloadable web-based software platform for laboratory and diagnostic equipment information management, monitoring and analysis; hosting of a web-based software platform for laboratory and diagnostic equipment information management, monitoring and analysis; providing information, including online, about all of the foregoing; all of the foregoing software-related services relating only to software for monitoring and controlling communication between computers and scientific/medical apparatus, software for operating and controlling 3D printers for scientific or medical purposes, downloadable operating software to control laboratory apparatus for fabrication of three dimensional (3D) engineered living tissues, and software for the purpose of the manufacture of medical products by means of a 3D printer; none of the foregoing services being in relation to oral or injectable therapies for the treatment of patient needs in the areas of fibrosis, lysosomal storage disorders and oncology, cardiometabolic diseases, liver diseases, metabolic disorders (including obesity, diabetes, severe dyslipidemias, NASH), inflammatory diseases and autoimmune diseases]

Type of Mark: Word

Date of Acceptance: Sept. 5

Registration Advertised: Nov. 12

For further details contact ALLENS PATENT & TRADE MARK ATTORNEYS.

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2361708.

Disclaimer: Curated by HT Syndication.